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HIV in Denmark
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Isik S. Johansen5, Gitte Pedersen6, Lars Nørregård Nielsen7, Jesper Bonde8,9, Terese L. Katzenstein4,
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Abstract
Background: Bacterial vaginosis (BV) has been found to be associated with HIV acquisition and transmission.
This is suggested to be due to higher HIV RNA levels in cervicovaginal fluids in women living with HIV (WLWH)
with BV, as bacteria associated with BV may induce viral replication and shedding in the genital tract despite
undetectable HIV RNA plasma viral load.
We examined the prevalence and diagnostic predictors of BV and HIV-1 RNA vaginal shedding in women living
with HIV (WLWH) in Denmark, taking into account the presence of human papillomavirus (HPV) and herpes viridae.
Methods: WLWH between 18–51 years were recruited from six Departments of Infectious Diseases in Denmark during
enrolment in the SHADE cohort; a prospective cohort study of WLWH attending regular outpatient care. BV was
diagnosed by microscopy of vaginal swabs and PCR was used for detection of BV-associated bacteria, HPV, herpes
viridae, and vaginal HIV viral load.
Results: Median age of the 150 included women was 41 years; ethnicity was predominantly White (35%) or Black
(47%). The majority (96%) was on ART and had undetectable (85%) plasma HIV RNA (<40 copies/mL).
BV was diagnosed in 32%. Overall, 11% had detectable vaginal HIV RNA. Both before and after adjustment for BV, age,
ethnicity, plasma HIV RNA, CD4 cell count, herpes viridae and HPV, we found no significant predictors of HIV RNA
vaginal shedding.
Conclusion: In well-treated WLWH, BV, herpes viridae or HPV do not predict vaginal HIV RNA shedding. This implies
that HIV shedding does not seem to be increased by BV.
Keywords: Women living with HIV, Bacterial vaginosis, HIV RNA vaginal shedding, Herpes viridae, Human papilloma virus
Background
Bacterial vaginosis (BV) is characterized by an over-
growth of anaerobic bacteria and a relative loss of
lactobacillus species. This leads to an increase in vaginal
pH and a malodorous vaginal discharge [1]. Bacterial
vaginosis is associated with complications such as
miscarriage, premature birth, pelvic inflammatory dis-
ease and tubal factor infertility [2].
Studies have shown a high incidence of BV among
women living with Human Immunodeficiency Virus-1
(WLWH) (HIV) and an increased risk of both HIV acqui-
sition and HIV transmission in women with BV [3, 4].
The association between BV and an increased rate of
HIV transmission has been suggested to include several
mechanisms; a higher HIV RNA concentration has been
found in cervicovaginal fluids in WLWH with BV, [5]
and bacteria associated with BV may induce viral
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replication and shedding in the genital tract [6]. Both
components may lead to increased HIV transmission
[4]. A study from sub-Saharan Africa showed that BV
was associated with a three-fold higher risk of HIV
female-to-male transmission among sero-discordant
couples [4]. However, in most conducted studies,
WLWH did not receive antiretroviral treatment (ART)
which reduces the HIV transmission significantly [7].
On the other hand, Alcaide et al. [8] showed that in
128 Zambian WLWH on ART, plasma HIV RNA levels
were significantly associated with vaginal HIV RNA
shedding, while BV was not.
The aim of the study was to investigate the prevalence
of BV and vaginal HIV RNA shedding and to identify
diagnostic predictors, including herpes viridae and hu-
man papilloma virus (HPV), of BV and HIV RNA vaginal
shedding in predominantly well-treated WLWH.
Methods
Study setting
Denmark has a population of 5.6 million inhabitants,
with an estimated 5000 HIV-infected individuals of
which 1400 are women [9]. Annually, 250–300 individ-
uals are diagnosed with HIV [10]. Medical care, includ-
ing ART, is provided free of charge [11]. WLWH
>18 years were recruited from six Departments of
Infectious Diseases in Denmark (Copenhagen University
Hospitals, Hvidovre and Rigshospitalet, Aarhus University
Hospital, Skejby, Odense University Hospital, Nordsjæl-
lands Hospital and Aalborg University Hospital) during
enrolment in the SHADE (Study on HIV, cervical Abnor-
malities and infections in women in Denmark) [12]. The
SHADE cohort is a prospective cohort study of WLWH
in Denmark [12]. A cut-off age of 51 years was chosen as
the median age for menopause is 51 years and a micro-
scopic BV diagnosis is questionable in post-menopausal
women [13]. Exclusion criterion was pregnancy. Collec-
tion of samples took place between February 2013 and
March 2014.
Danish HIV cohort study
The Danish HIV Cohort Study is a nationwide, prospect-
ive, observational, multicentre, population-based cohort
study of all People Living with HIV (PLWH) seen at
Danish Departments of Infectious Diseases since 1 January
1995 [11]. The database is updated annually and contains
extensive data on PLWH, e.g. demographic data, date
of HIV diagnosis, ART regimen, CD4 counts and
HIV RNA levels [11].
The civil registration system
The Civil Registrations System is a national registry of
all Danish residents [14]. At birth or immigration a
unique, 10-digit personal identification number (PIN) is
assigned to each individual. The PIN was used to link
the Danish HIV Cohort Study to the SHADE cohort.
Ethical statement
The study was approved by the Danish Data Protection
Agency (2015–231-0126, 2012–58-0004 and 2012–41-
0005) and the Danish Regional Committee on Health
Research Ethics (H-3-2010-119 and H-2-2014-102). All
patients signed informed consent.
Microscopy - detection of bacterial vaginosis
Vaginal swabs were taken and a flocked swab was col-
lected in Universal Transport Medium (Copan, Brescia,
Italy) and sent to Statens Serum Institut, Copenhagen.
The smears were Gram stained and slides were evalu-
ated by the same observer. Each sample was scored on
an average of at least five field views according to the
Nugent score: Grade I (score 0–3): normal flora; grade II
(score 4–6): intermediary stage and grade III (score 7–
10): BV. [1] The microscopy diagnosis is used in the
statistical analyses, as Nugent’s scoring system is consid-
ered gold standard.
PCR – Detection of bacterial vaginosis
Quantitative real-time polymerase chain reaction (qPCR)
of vaginal swabs for detection of: Atopobium vaginae,
Megasphaera type 1, Bacterial Vaginosis Associated Bac-
terium type 1 (BVAB1) and Prevotella spp. was carried
out as previously described [15]. The bacterium BVAB1
was used as it has been shown to be significantly associ-
ated with high Nugent scores [16]. The remaining three
bacteria were used as they previously have been shown
to have good sensitivity and specificity in PCR analysis
[15, 17, 18].
When at least one of the abovementioned four bac-
teria was above the cut-off value, the test was considered
positive for BV. Cut-off values for the four bacteria were
used as described by Datcu et al. [15].
PCR - detection of vaginal HIV RNA
Vaginal swabs were collected and placed in 3 mL Copan
Universal Transport medium (Copan, Brescia, Italy) and
frozen at −80 °C. Between 0.3 mL - 1.0 mL was available
from each swab. Samples were thawed at room
temperature, thoroughly vortexed and centrifuged for
one hour at 17,000 G. The pellet was dissolved in
1.0 mL phosphate-buffered saline. HIV RNA was mea-
sured using AmpliPrep (Roche Molecular Systems, Inc.)
and COBAS TaqMan 48 (COBAS TaqMan HIV test,
v2.0, Roche Molecular Systems, Inc.). Results are pre-
sented as copies HIV RNA/swab. Detection limit for the
COBAS TaqMan is 20 copies/mL and lowest detected
level in our samples was ≥66 copies/swab.
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The test was validated prior to study analysis; 10 sam-
ples of Copan Universal Transport medium with a
known concentration of HIV RNA were analysed using
the same procedure as recommended by the manufac-
turer – validating the test for use in this medium.
PCR - human papillomavirus
Cervical samples were examined for 35 defined high and
low risk HPV by the CLART HPV2 assay (Genomica,
Madrid, Spain). The assay detects genotype specific HPV
L1 fragments from HPV6, 11, 16, 18, 26, 31, 33, 35, 39,
40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66,
68, 70, 71, 72, 73, 81, 82, 83, 84, 85 and 89 [19]. Analyt-
ical DNA extractions were conducted using the MagNA-
Pure LC96 (LC Total Nuclei Acid kit, Roche Molecular
Systems, Rotkreuz, Switzerland).
PCR – herpes viridae
Diagnostics on vaginal swabs was conducted using the
Entherpex PCR microarray system in concordance with
manufacturer’s specifications (Genomica, Madrid, Spain).
The array simultaneously detects: Herpes simplex virus 1
and 2, Cytomegalovirus, Epstein-Barr virus, Human her-
pes virus 6 and 7, and Varicella zoster virus.
Both HPV and herpes virus analyses were done at
the Department of Pathology, Copenhagen University
Hospital, Hvidovre, Denmark.
Statistical analyses
Categorical variables were reported as counts and per-
centages and compared by chi-square test or Fisher’s
exact test, as appropriate. Continuous variables were
summarized as median and interquartile ranges (IQR)
and compared using the Wilcoxon rank sum test. Uni-
and multiple logistic regression analyses were performed
to identify predictors of HIV RNA vaginal shedding and
BV. Odds ratios (ORs) and 95% confidence intervals
were estimated and adjusted for candidate predictor
variables chosen a priori; age at inclusion (<40 versus
≥40 years), ethnicity, plasma HIV RNA (<40 versus ≥40
copies/mL), CD4 count (<200, ≥200–349 and ≥350 cells/μL),
herpes PCR positive, HPV PCR positive, and BV (positive by
microscopy). The validity of the model was tested using the
Hosmer and Lemeshow Goodness-of-Fit Test. Individuals
with missing explanatory values were excluded from the
multiple regression analyses, i.e. considered missing at
random. SAS statistical software version 9.3 (SAS
Institute Inc., Cary, NC, USA) was used for data ana-
lysis and p-values below 0.05 (two-sided) were consid-
ered statistically significant.
Results of BV were statistically analysed using Nugent
score, as this is the gold standard of BV diagnosis [1].
Results
Demographics (Table 1)
Two hundred thirty-four WLWH were eligible for inclu-
sion [12]. Of these, 34 were excluded as samples for mi-
croscopy (n = 3) or vaginal HIV RNA (n = 31) analyses
were missing and 50 women were excluded as they were
51 years or older, leaving 150 women included in the
study. Table 1 shows the baseline demographic charac-
teristics. The median age was 41 years and ethnicity was
predominantly Black (47%) or White (35%). The vast
majority of women were on ART and 85% had undetect-
able plasma HIV RNA (<40 copies/mL).
Ninety-four percent were heterosexually infected, most
had <15 lifetime sexual partners. Symptoms from the
lower abdomen were reported by 23% of the women.
Most commonly reported symptoms included increased
vaginal discharge, bleeding disturbances and pain during
intercourse.
Bacterial vaginosis and vaginal HIV RNA shedding (Table 2)
Table 2 shows that Nugent grade III was found in 32%
of the women, grade II in 37% and grade I in 31%. When
microscopy and PCR were combined by including all
women with grade III together with any BV associated
bacterium present above threshold, 40% of the women
were positive for BV. Also shown in Table 2 are the re-
sults of the four bacteria associated with BV, analysed
with PCR. There was no statistically significant associ-
ation between HIV RNA vaginal shedding and BV
diagnosed with microscopy or PCR. The only statistically
significant finding in the analysis was being PCR nega-
tive for Prevotella spp. (p = 0.038).
There was no significant difference in BV diagnosis be-
tween women of White and Black ethnicity (p = 0.21).
There was no difference in reported symptoms from the
lower abdomen or number of lifetime sexual partners
according to BV status. Further, we found no correlation
between BV status and detectable plasma HIV RNA.
Treatment with protease inhibitors (PIs) was not associ-
ated with BV (p = 0.28) but non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) treatment was positively
associated with BV (p = 0.047). Seventy-five WLWH
received PIs and of those, 20 had BV while 62 WLWH
received NNRTI’s and of those 25 had BV.
Predictors of vaginal HIV RNA shedding (Table 3)
The range for detectable HIV RNA in vaginal swabs was
66–31,650 copies/swab with a median value of 191 cop-
ies/swab. Overall, 11% of the women had detectable va-
ginal HIV RNA (≥66 copies/swab). Of these, 94% were
on ART. Two women that were positive for vaginal HIV
RNA shedding, had detectable plasma HIV RNA levels
(> 40 copies/mL), for three women the plasma levels
were missing. Of the 11% of women positive for vaginal
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HIV RNA shedding, 29% had BV. There was no signifi-
cant association between ART regimen and vaginal HIV
RNA shedding.
There was no difference in vaginal HIV RNA shedding
according to BV status (p = 0.21). None of the chosen
variables predicted vaginal HIV RNA shedding in the ad-
justed analyses. The Hosmer and Lemeshow Goodness-
of-Fit tests demonstrated sufficient fit (p = 0.097,
p = 0.29).
Predictors of bacterial vaginosis (Table 4)
Table 4 shows predictors of bacterial vaginosis. When
analyzing age at inclusion, ethnicity, plasma viral load,
CD4 cell counts, herpes viridae, HPV or vaginal HIV
RNA shedding, no significant predictors of BV were
found, apart from suppressed viral load (p = 0.05).
Discussion
This study examined the prevalence and diagnostic
predictors of BV and HIV RNA vaginal shedding in
Danish WLWH, while also taking into account HPV and
herpes viridae.
In this nationwide study of 150 predominantly well-
treated WLWH the overall BV prevalence by Nugent
score was 32% and HIV RNA was detected in 11% of
vaginal swabs. However, no predictors of HIV RNA vagi-
nal shedding were found, including being BV positive.
Furthermore, the presence of vaginal herpes viridae and/
or HPV or vaginal HIV RNA shedding did not predict BV.
Bacterial vaginosis and vaginal HIV RNA shedding
Similar to our results, a study among 311 American
WLWH aged 18–45 years, found a BV prevalence
(Nugent’s criteria used for diagnosis) of 36% [20]. Not-
ably, almost half of the study participants were not
receiving ART, more than two-thirds had CD4 cell
counts below 500 cells/mm3 and the majority were of
Black ethnicity [20]. Despite the higher rate of well-
treated women in the present study, we found a com-
parable BV prevalence, confirming that BV is highly
prevalent, irrespective of ART. In comparison, a Danish
study of the general population found that 16% of 880
women aged 15–45 years had BV according to Nugent’s
Table 1 Baseline characteristics of 150 women living with HIV,
included in the study
Demographic data Study Participants
Duration of HIV infection (years), median (IQR) 11.3 (6.6–16.1)
Age at inclusion (years), median (IQR) 41.1 (36.5–45.5)
Ethnicity, n (%)
Black 71 (47.3)
White 53 (35.3)
Asian 24 (16.0)
Other 2 (1.3)
Place of HIV transmission, n (%)
Denmark 45 (32.4)
Europe + US 13 (9.4)
Africa 61 (43.9)
Asia 20 (14.4)
(missing) (11)
Mode of transmission, n (%)
Heterosexual 137 (93.8)
IDUa 4 (2.7)
Other 5 (3.4)
(missing) (4)
CD4 count (cells/μl), n (%)
< 200 4 (2.9)
200–350 18 (13.0)
> 350 118 (84.1)
(missing) (11)
ART, n (%)
Yes 144 (96.0)
No 6 (4.0)
ART groups, n (%)
2 NRTI’s + 1 NNRTI 59 (50.0)
2 NRTI’s + PI’s 65 (45.1)
Other regimen 20 (13.9)
AIDS prior to inclusion n (%)
Yes 20 (13.3)
No 130 (86.7)
Number of lifetime sexual partners
< 5 38 (25.3)
5–14 62 (41.3)
15–25 24 (16.0)
> 25 25 (16.7)
Does not want to respond 1 (0.7)
Current use of contraception n (%)
Condom Yes 67 (44.7)
Condom No 83 (55.3)
Table 1 Baseline characteristics of 150 women living with HIV,
included in the study (Continued)
Symptomsb from the lower abdomen
Yes 35 (23.3)
No 115 (76.7)
ART groups: NRTI Nucleoside Reverse Transcriptase Inhibitors, NNRTI
Non-Nucleoside Reverse Transcriptase Inhibitors, PI Protease Inhibitors
aIDU Intravenous Drug Use
bSymptoms included: increased vaginal discharge, disturbing vaginal smell,
burning sensation upon urination, bleeding disturbances, bleeding during
intercourse, pain during intercourse, general pain and “other”
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criteria [21]. Women were included from one general
practice, where they attended the clinic due to abnor-
mal vaginal discharge, other genito-urinary symptoms
or for a routine check-up [21]. On the other hand, a
study from a Sexually Transmitted Infections (STI’s)
clinic in Copenhagen where 76 women with symptoms
from the lower abdomen were examined for STI’s,
found BV to be the leading cause of vaginal discharge
Table 2 Prevalence of Bacterial Vaginosis, vaginal HIV RNA shedding and plasma HIV RNA viral load in 150 women living with HIV
included in the study
Diagnosis Study Participants
n (% of all participants)
Positive for vaginal HIV RNA shedding
n (% of total)
Combined p-value
Bacterial vaginosis (BV), Nugent scorea
Grade I 47 (31.3) 5 (10.6) -
Grade II 55 (36.7) 7 (12.7) -
Grade III 48 (32.0) 5 (10.4) 0.92
Bacterial vaginosis (PCR)
Atopobium Vaginae positive 44 (30.1) 5 (11.4) -
Atopobium Vaginae negative 102 (69.9) 12 (11.8) 0.94
(missing) (4)
Bacterial vaginosis (PCR)
Megasphaera positive 34 (22.8) 3 (8.8) -
Megasphaera negative 115 (77.2) 14 (12.2) 0.59
(missing) (1)
Bacterial vaginosis (PCR)
BVAB1 positive 9 (6.1) 1 (11.1) -
BVAB1 negative 139 (93.9) 15 (10.8) 0.98
(missing) (2)
Bacterial vaginosis (PCR)
Prevotella positive 40 (26.9) 1 (2.5) -
Prevotella negative 109 (73.1) 16 (14.7) 0.038
(missing) (1)
Bacterial vaginosis (PCR)
At least one bacteria positive with PCR 54 (36.0) 5 (9.3) -
All bacteria negative with PCR 96 (64.0) 12 (12.5) 0.55
Combined PCR and microscopy
Positive 60 (40.0) 6 (10.0) -
Negative 90 (60.0) 11 (12.2) 0.67
BV positive, by ethnicity
White 22 (45.8) 6 (11.3) -
Black 18 (37.5) 1 (4.2) -
Asian 7 (14.6) 10 (14.1) -
Other 1 (2.1) 0 (0) 0.59
Vaginal HIV RNA
Detectable ≥66 copies/swab) 17 (11.3) - -
Not detectable (<66 copies/swab) 133 (88.7) - -
Plasma HIV RNA < 40 copies/mL
Detectable 21 (15.2) 2 (1.5) -
Not detectable 117 (84.8) 11 (9.4) 1.0
(missing) (12)
a Nugent score Grade I = normal flora, Grade II = intermediate flora, Grade III = Bacterial vaginosis
Wessman et al. BMC Infectious Diseases  (2017) 17:376 Page 5 of 10
with a prevalence of 62% (method of diagnosis not spe-
cified) [22]. Women in our study, however, were exam-
ined regardless of symptoms, which might explain the
lower occurrence of BV compared to women attending
an STI clinic with complaints of symptoms from the
lower abdomen. However, our study population had
double the amount of positive BV smears compared to
a sample from the general population, which may be
explained by the presence of HIV infection.
It has previously been shown that women of Black eth-
nicity have a higher prevalence of BV (diagnosed with
Amsel’s criteria), compared to women of White ethnicity
[23]. However, in the present study, no difference in BV
between women of Black and White ethnicity was found.
The lack of difference between the two populations may
be due to the small sample size or different cultural
practices in a Danish setting, compared to American or
sub-Saharan settings [24, 25].
Molecular methods for detection of BV-associated bac-
teria were used in order to be able to also classify women
with intermediate (Nugent II) flora and with an aim to
sub-classify BV according to the dominating bacterial
composition. However, neither the classification according
to presence of bacterial loads above threshold, nor the
Table 3 Predictors for vaginal HIV RNA shedding in 150 women living with HIV, included in the study. Unadjusted and adjusted for:
age at inclusion, ethnicity, plasma HIV RNA, CD4 cell count, herpes viridae DNA, HPV and bacterial vaginosis (Nugent score)
Predictors of vaginal HIV RNAa Vaginal HIV RNA
shedding positive
(n = 17)
Vaginal HIV RNA
shedding negative
(n = 133)
Unadjusted
odds ratios
p-value Adjusted
odds ratios
p-value
Age at inclusion (years), n (%)
< 40 6 (9.8) 55 (90.2) 1.00 - 1.00 -
≥ 40 11 (12.4) 78 (87.6) 1.29 (0.45–3.71) 0.63 1.43 (0.34–6.00) 0.63
Ethnicity, n (%)
White 6 (11.3) 47 (88.7) 1.00 - 1.00 -
Asian 1 (4.2) 23 (95.8) 0.34 (0.04–3.0) 0.33 0.67 (0.06–7.27) 0.74
Black 10 (14.1) 61 (85.9) 1.28 (0.44–3.79) 0.65 1.70 (0.41–7.16) 0.47
(missing) (0) (2)
Combined p-value 0.73 0.60
HIV RNA (copies/ml), n (%)
≥ 40 2 (9.5) 19 (90.5) 1.00 - 1.00 -
< 40 11 (9.4) 106 (90.6) 0.99 (0.20–4.80) 0.99 1.19 (0.21–6.63) 0.85
(missing) (4) (8)
CD4 count (cells/μl), n (%)
< 350 2 (9.1) 20 (90.9) 1.00 - 1.00 -
≥ 350 11 (9.4) 106 (90.6) 1.04 (0.21–5.04) 0.96 1.15 (0.22–6.09) 0.87
(missing) (4) (7)
Herpes viridae PCR positive, n (%)
Yes 7 (13.5) 45 (86.5) 1.00 - 1.00 -
No 9 (9.6) 85 (90.4) 0.68 (0.24–1.95) 0.47 0.83 (0.21–3.26) 0.79
(missing) (1) (3)
HPVb PCR positive, n (%)
Yes 10 (14.9) 57 (85.1) 1.00 - 1.00 -
No 6 (8.8) 62 (91.2) 0.55 (0.19–1.62) 0.23 0.73 (0.21–2.60) 0.63
(missing) (1) (14)
BVc by Nugent score, n (%)
Yes 5 (10.4) 43 (89.4) 1.00 - 1.00 -
No 12 (11.8) 90 (88.2) 1.15 (0.38–3.46) 0.81 1.80 (0.43–7.62) 0.42
a The validity of the model was tested using the Hosmer and Lemeshow Goodness-of-Fit Test
b HPV human papilloma virus
c Bacterial vaginosis
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stratification according to the individual BV-defining spe-
cies showed any correlation with HIV shedding.
We found a vaginal HIV RNA prevalence of 11%.
Similarly, Neely et al. [26] detected HIV RNA in 15% of
cervical swabs obtained from 290 well treated WLWH.
The authors found that shedding was associated with
NNRTI use versus PI use and illicit drug use, while no
correlation was found between HIV RNA shedding and
BV, as more non-shedders than shedders were diagnosed
with BV (21% versus 16%) [26]. We found no association
between PIs, NNRTIs and vaginal HIV RNA shedding.
However, BV was associated with NNRTI use. The rea-
son for this association may be spurious, although
NNRTIs seem to have lower concentration in genital
fluids compared to PIs [27]. Though vaginal HIV RNA
shedding has been shown to correlate with plasma HIV
RNA, a separate reservoir of vaginal HIV RNA has also
been described [20].
Due to a lack of statistical power (12 women on hor-
monal contraceptives and one with vaginal HIV RNA
shedding) hormonal contraception was not included in
the analyses as a possible predictor of vaginal HIV RNA
shedding in our study.
Predictors of bacterial vaginosis and vaginal HIV RNA
shedding
We found no statistically significant association between
HIV RNA vaginal shedding and BV. The significant
Table 4 Table over predictors of bacterial vaginosis in 150 women living with HIV, included in the study. Unadjusted and adjusted
for: age at inclusion, ethnicity, plasma HIV RNA, CD4 cell count, herpes viridae, human papilloma virus and vaginal HIV RNA shedding
Predictors of Bacterial Vaginosisa BVb positive
(n = 48)
BV negative
(n = 102)
Unadjusted odds ratios p-value Adjusted odds ratios p-value
Age at inclusion (years), n (%)
< 40 23 (37.7) 38 (62.3) 1.00 - 1.00 -
≥ 40 25 (28.1) 64 (71.9) 0.65 (0.32–1.29) 0.22 0.63 (0.26–1.49) 0.29
Ethnicity, n (%)
White 22 (41.5) 31 (58.5) 1.00 - 1.00 -
Asian 7 (29.2) 17 (70.8) 0.58 (0.21–1.64) 0.30 0.36 (0.10–1.29) 0.12
Black 18 (25.4) 53 (74.6) 0.06 0.06
(missing) (1) (1) 0.48 (0.22–1.03) 0.42 (0.17–1.03)
Combined p-value 0.16 0.11
Plasma HIV RNA (copies/ml), n (%)
≥ 40 3 (14.3) 18 (85.7) 1.00 - 1.00 -
< 40 40 (34.2) 77 (65.8) 3.12 (0.87–11.22) 0.082 4.0 (1.02–15.65) 0.05
(missing) (5) (7)
CD4 count (cells/μl), n (%)
< 350 4 (18.2) 18 (81.8) 1.00 - 1.00 -
≥ 350 39 (33.3) 78 (66.7) 2.25 (0.71–7.10) 0.17 2.04 (0.61–6.83) 0.25
(missing) (5) (6)
Herpes PCR positive, n (%)
Yes 18 (34.6) 34 (65.4) 1.00 - 1.00 -
No 28 (29.8) 66 (70.2) 0.80 (0.39–1.65) 0.55 1.08 (0.43–2.70) 0.87
(missing) (2) (2)
HPVc PCR positive, n (%)
Yes 23 (34.3) 44 (65.7) 1.00 - 1.00 -
No 19 (27.9) 49 (72.1) 0.74 (0.36–1.54) 0.42 0.88 (0.39–2.00) 0.76
(missing) (6) (9)
Vaginal HIV RNA shedding positive, n (%)
Yes 5 (29.4) 12 (70.6) 1.00 - 1.00 -
No 43 (32.3) 90 (67.7) 1.15 (0.38–3.46) 0.81 1.11 (0.26–4.84) 0.89
a The validity of the model was tested using the Hosmer and Lemeshow Goodness-of-Fit Test
b BV Bacterial Vaginosis
c HPV Human Papilloma Virus
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association of being PCR negative for Prevotella spp. and
HIV RNA vaginal shedding is considered to be signifi-
cant at random.
In an American study of 203 WLWH with BV di-
agnosed with Nugent score, herpes simplex virus,
but not HPV, was associated with HIV RNA in cer-
vicovaginal lavage samples [5]. However, all of these
women had plasma HIV RNA ≥4000 copies/mL, and
were thereby not applicable to our setting where
WLWH had fully suppressed plasma HIV RNA
levels [5].
It has previously been described that BV (diagnosed
with Amsel’s criteria) induces HIV RNA vaginal shed-
ding [28]. In 2013, Mitchell et al. [29] found an associ-
ation between genital HIV RNA shedding and BV
associated species (diagnosed using Nugent’s criteria)
among 104 WLWH on ART.
The association between BV and HIV acquisition/
transmission seems to be strong [30]. A meta-analysis
assessing 25 different study populations from the US,
Thailand and sub-Saharan Africa including almost
31,000 women, concluded that BV increases the risk of
HIV acquisition by approximately 60% [3]. In this meta-
analysis BV was diagnosed with Nugent’s criteria in 12/
25 study populations and by clinical criteria only in
13/25 study populations [3]. The overall BV preva-
lence was 33%, ranging from 11% in women aged 20–
35 years from the US to 70% in South African women
with symptoms of STI’s. [3] In a sub-Saharan African
study among 2236 sero-discordant couples, BV (diag-
nosed with Nugent’s criteria) was associated with a
more than three-fold higher risk of HIV female-male
transmission, after controlling for socio-demographic
factors, sexual behaviour, male circumcision, STIs,
pregnancy and plasma HIV RNA levels [4]. While a
high prevalence of BV was also found in the present
study, most patients were on suppressive ART with
low vaginal viral loads, unlike most patients in the
abovementioned studies, and we found no relation
between BV status and vaginal HIV RNA shedding. Our
findings emphasize the importance of ART, and support
the treatment as prevention studies, where patients on
ART are unlikely to transmit HIV [31].
In the current study, around 40% of women with
symptoms from the lower abdomen were BV positive
but we found no associations between having symptoms
and BV. In line with this, an American study of 2888
women without gonorrhoea or trichomonas found a
high prevalence of symptoms in both women with and
without BV, and with no significant difference between
the groups [32]. All BV diagnoses were made by using
Nugent’s criteria.
Bacterial vaginosis is often asymptomatic, under-
diagnosed and –treated [32].
Strengths of the present study are that all microscopy
samples were analysed by the same observer and the na-
tionwide inclusion, thereby giving a wider image of the
female HIV-infected population in Denmark. Our cohort
has previously been shown to include very few other
STI’s, [12] which is why no further testing was made in
the present study. Furthermore, the molecular methods
allowed an objective determination of BV in the group
with intermediate flora and had the potential to sub-
classify BV according to the dominating species.A limi-
tation may be the relatively small number of included
patients, representing 14% of Denmark’s WLWH. Also,
the inclusion and exclusion criteria might have led to
the elimination of high-risk patients, as there were sig-
nificantly less intravenous drug users included in the
study, as well as more women on ART with lower HIV
RNA counts and higher CD4 cell counts. (Thorsteins-
son K, personal communication) However, there was
no significant difference in ethnicity between the two
groups. (Thorsteinsson K, personal communication).
Finally, analysis for Gardnerella vaginalis, BVAB2,
Eggerthella-like bacterium, and Leptotrichia amnionii
could have been considered for analysis, however, these
bacteria overlap significantly in their presence with the
current selection [15], and it was considered to be too
costly to include these additional species. Rather, it
should be considered to re-analyse the samples using
16S rRNA gene based deep-sequencing to more thor-
oughly characterise the vaginal microbiota.
Conclusion
BV is highly prevalent among well-treated women living
with HIV in Denmark and more than 10% are positive
for vaginal HIV RNA shedding. However, in this popula-
tion, BV, herpes viridae and HPV do not predict vaginal
HIV RNA shedding and, importantly, do thereby not
seem to increase the risk of HIV transmission to part-
ners or new-borns.
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